Repetitive transcranial magnetic stimulation for the treatment of executive function deficits in autism spectrum disorder

Clinical trial approach

Stephanie H. Ameis, Zafiris J. Daskalakis, Daniel M. Blumberger, Pushpal Desarkar, Irene Drmic, Donald J. Mabbott, Meng Chuan Lai, Paul E Croarkin, Peter Szatmari

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Objective: Executive function (EF) deficits in patients with autism spectrum disorder (ASD) are ubiquitous and understudied. Further, there are no effective, neuroscience-based treatments to address this impairing feature of ASD. Repetitive transcranial magnetic stimulation (rTMS) has demonstrated promise in addressing EF deficits in adult neuropsychiatric disorders. This article will outline the design of a novel randomized-controlled trial of bilateral, 20 Hz, rTMS applied to the dorsolateral prefrontal cortex (DLPFC) for treatment of EF deficits in ASD that is currently ongoing. We describe prior therapeutic rTMS research for ASD and prior rTMS trials targeting EFs in adult neuropsychiatric disorders. A neurophysiological rationale for rTMS treatment of EF deficits in ASD is presented. Methods: An ongoing protocol will enroll participants aged 16-35 with ASD and no intellectual disability. Psychotropic medications will be continued during the 4-week trial of active 20 Hz versus sham rTMS applied to the DLPFC. Twenty, active treatment sessions consisting of 25 stimulation trains at a 90% motor threshold will be administered. The primary outcome measure is the Cambridge Neuropsychological Test Automated Battery (CANTAB) spatial working memory task. At present, recruitment, enrollment, and treatment within the described clinical trial are ongoing. Conclusions: EF deficits are common and impairing symptoms of ASD. There are no evidence-based treatments for EF deficits in ASD. The protocol described here will provide important preliminary data on the feasibility and efficacy of 20 Hz rTMS to DLPFC for EF deficits in ASD.

Original languageEnglish (US)
Pages (from-to)413-421
Number of pages9
JournalJournal of Child and Adolescent Psychopharmacology
Volume27
Issue number5
DOIs
StatePublished - Jun 1 2017

Fingerprint

Transcranial Magnetic Stimulation
Executive Function
Clinical Trials
Prefrontal Cortex
Therapeutics
Autism Spectrum Disorder
Neuropsychological Tests
Neurosciences
Short-Term Memory
Intellectual Disability
Randomized Controlled Trials
Outcome Assessment (Health Care)

Keywords

  • Asperger's disorder
  • autistic disorder
  • executive function deficits
  • repetitive transcranial magnetic stimulation
  • treatment

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Psychiatry and Mental health
  • Pharmacology (medical)

Cite this

Repetitive transcranial magnetic stimulation for the treatment of executive function deficits in autism spectrum disorder : Clinical trial approach. / Ameis, Stephanie H.; Daskalakis, Zafiris J.; Blumberger, Daniel M.; Desarkar, Pushpal; Drmic, Irene; Mabbott, Donald J.; Lai, Meng Chuan; Croarkin, Paul E; Szatmari, Peter.

In: Journal of Child and Adolescent Psychopharmacology, Vol. 27, No. 5, 01.06.2017, p. 413-421.

Research output: Contribution to journalArticle

Ameis, Stephanie H. ; Daskalakis, Zafiris J. ; Blumberger, Daniel M. ; Desarkar, Pushpal ; Drmic, Irene ; Mabbott, Donald J. ; Lai, Meng Chuan ; Croarkin, Paul E ; Szatmari, Peter. / Repetitive transcranial magnetic stimulation for the treatment of executive function deficits in autism spectrum disorder : Clinical trial approach. In: Journal of Child and Adolescent Psychopharmacology. 2017 ; Vol. 27, No. 5. pp. 413-421.
@article{22a5078c22904d8db573dec7d368e96a,
title = "Repetitive transcranial magnetic stimulation for the treatment of executive function deficits in autism spectrum disorder: Clinical trial approach",
abstract = "Objective: Executive function (EF) deficits in patients with autism spectrum disorder (ASD) are ubiquitous and understudied. Further, there are no effective, neuroscience-based treatments to address this impairing feature of ASD. Repetitive transcranial magnetic stimulation (rTMS) has demonstrated promise in addressing EF deficits in adult neuropsychiatric disorders. This article will outline the design of a novel randomized-controlled trial of bilateral, 20 Hz, rTMS applied to the dorsolateral prefrontal cortex (DLPFC) for treatment of EF deficits in ASD that is currently ongoing. We describe prior therapeutic rTMS research for ASD and prior rTMS trials targeting EFs in adult neuropsychiatric disorders. A neurophysiological rationale for rTMS treatment of EF deficits in ASD is presented. Methods: An ongoing protocol will enroll participants aged 16-35 with ASD and no intellectual disability. Psychotropic medications will be continued during the 4-week trial of active 20 Hz versus sham rTMS applied to the DLPFC. Twenty, active treatment sessions consisting of 25 stimulation trains at a 90{\%} motor threshold will be administered. The primary outcome measure is the Cambridge Neuropsychological Test Automated Battery (CANTAB) spatial working memory task. At present, recruitment, enrollment, and treatment within the described clinical trial are ongoing. Conclusions: EF deficits are common and impairing symptoms of ASD. There are no evidence-based treatments for EF deficits in ASD. The protocol described here will provide important preliminary data on the feasibility and efficacy of 20 Hz rTMS to DLPFC for EF deficits in ASD.",
keywords = "Asperger's disorder, autistic disorder, executive function deficits, repetitive transcranial magnetic stimulation, treatment",
author = "Ameis, {Stephanie H.} and Daskalakis, {Zafiris J.} and Blumberger, {Daniel M.} and Pushpal Desarkar and Irene Drmic and Mabbott, {Donald J.} and Lai, {Meng Chuan} and Croarkin, {Paul E} and Peter Szatmari",
year = "2017",
month = "6",
day = "1",
doi = "10.1089/cap.2016.0146",
language = "English (US)",
volume = "27",
pages = "413--421",
journal = "Journal of Child and Adolescent Psychopharmacology",
issn = "1044-5463",
publisher = "Mary Ann Liebert Inc.",
number = "5",

}

TY - JOUR

T1 - Repetitive transcranial magnetic stimulation for the treatment of executive function deficits in autism spectrum disorder

T2 - Clinical trial approach

AU - Ameis, Stephanie H.

AU - Daskalakis, Zafiris J.

AU - Blumberger, Daniel M.

AU - Desarkar, Pushpal

AU - Drmic, Irene

AU - Mabbott, Donald J.

AU - Lai, Meng Chuan

AU - Croarkin, Paul E

AU - Szatmari, Peter

PY - 2017/6/1

Y1 - 2017/6/1

N2 - Objective: Executive function (EF) deficits in patients with autism spectrum disorder (ASD) are ubiquitous and understudied. Further, there are no effective, neuroscience-based treatments to address this impairing feature of ASD. Repetitive transcranial magnetic stimulation (rTMS) has demonstrated promise in addressing EF deficits in adult neuropsychiatric disorders. This article will outline the design of a novel randomized-controlled trial of bilateral, 20 Hz, rTMS applied to the dorsolateral prefrontal cortex (DLPFC) for treatment of EF deficits in ASD that is currently ongoing. We describe prior therapeutic rTMS research for ASD and prior rTMS trials targeting EFs in adult neuropsychiatric disorders. A neurophysiological rationale for rTMS treatment of EF deficits in ASD is presented. Methods: An ongoing protocol will enroll participants aged 16-35 with ASD and no intellectual disability. Psychotropic medications will be continued during the 4-week trial of active 20 Hz versus sham rTMS applied to the DLPFC. Twenty, active treatment sessions consisting of 25 stimulation trains at a 90% motor threshold will be administered. The primary outcome measure is the Cambridge Neuropsychological Test Automated Battery (CANTAB) spatial working memory task. At present, recruitment, enrollment, and treatment within the described clinical trial are ongoing. Conclusions: EF deficits are common and impairing symptoms of ASD. There are no evidence-based treatments for EF deficits in ASD. The protocol described here will provide important preliminary data on the feasibility and efficacy of 20 Hz rTMS to DLPFC for EF deficits in ASD.

AB - Objective: Executive function (EF) deficits in patients with autism spectrum disorder (ASD) are ubiquitous and understudied. Further, there are no effective, neuroscience-based treatments to address this impairing feature of ASD. Repetitive transcranial magnetic stimulation (rTMS) has demonstrated promise in addressing EF deficits in adult neuropsychiatric disorders. This article will outline the design of a novel randomized-controlled trial of bilateral, 20 Hz, rTMS applied to the dorsolateral prefrontal cortex (DLPFC) for treatment of EF deficits in ASD that is currently ongoing. We describe prior therapeutic rTMS research for ASD and prior rTMS trials targeting EFs in adult neuropsychiatric disorders. A neurophysiological rationale for rTMS treatment of EF deficits in ASD is presented. Methods: An ongoing protocol will enroll participants aged 16-35 with ASD and no intellectual disability. Psychotropic medications will be continued during the 4-week trial of active 20 Hz versus sham rTMS applied to the DLPFC. Twenty, active treatment sessions consisting of 25 stimulation trains at a 90% motor threshold will be administered. The primary outcome measure is the Cambridge Neuropsychological Test Automated Battery (CANTAB) spatial working memory task. At present, recruitment, enrollment, and treatment within the described clinical trial are ongoing. Conclusions: EF deficits are common and impairing symptoms of ASD. There are no evidence-based treatments for EF deficits in ASD. The protocol described here will provide important preliminary data on the feasibility and efficacy of 20 Hz rTMS to DLPFC for EF deficits in ASD.

KW - Asperger's disorder

KW - autistic disorder

KW - executive function deficits

KW - repetitive transcranial magnetic stimulation

KW - treatment

UR - http://www.scopus.com/inward/record.url?scp=85020790496&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020790496&partnerID=8YFLogxK

U2 - 10.1089/cap.2016.0146

DO - 10.1089/cap.2016.0146

M3 - Article

VL - 27

SP - 413

EP - 421

JO - Journal of Child and Adolescent Psychopharmacology

JF - Journal of Child and Adolescent Psychopharmacology

SN - 1044-5463

IS - 5

ER -